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Pharmacokinetic evaluation of the interaction between oral 
kaempferol and ethanol in rats
This study was aimed at investigating the effect of ethanol 
on oral bioavailability of kaempferol in rats, namely, at dis-
closing their possible interaction. Kaempferol (100 or 250 
mg kg–1 bm) was administered to the rats by oral gavage 
with or without ethanol (600 mg kg–1 bm) co-administra-
tion. Intravenous administration (10 and 25 mg kg–1 bm) of 
kaempferol was used to determine the bioavailability. The 
concentration of kaempferol in plasma was estimated by 
ultra high performance liquid chromatography. During co-
administration, a significant increase of the area under the 
plasma concentration-time curve as well as the peak con-
centration were observed, along with a dramatic decrease 
in total body clearance. Consequently, the bioavailability of 
kaempferol in oral control groups was 3.1 % (100 mg kg–1 
bm) and 2.1 % (250 mg kg–1 bm). The first was increased by 
4.3 % and the other by 2.8 % during ethanol co-administra-
tion. Increased permeability of cell membrane and ethanol-
kaempferol interactions on CYP450 enzymes may enhance 
the oral bioavailability of kaempferol in rats.
Keywords: kaempferol, bioavailability, pharmacokinetics, 
ethanol, cytochrome P450s
As a representative flavonoid, kaempferol (3,4’,5,7-tetrahydroxyflavone, Mr 286.2) is 
mostly distributed in medicinal plants, vegetables and fruits (1). In clinics, numerous stud-
ies have demonstrated that kaempferol possesses far-ranging pharmacological activities, 
especially antioxidant (2) and anti-cancer ones (3). However, the oral bioavailability of 
kaempferol is relatively low because of its low lipid solubility and its limited membrane 
permeability (4). Some reports indicate that the efficiency of intestinal absorption of some 
flavones is strongly affected by their solubility in the vehicles (5). Consequently, the thera-
peutic effect of kaempferol is restricted to oral administration (4).
Alcoholic liver disease is caused by consuming a large quantity of alcoholic beverages 
over a long period of time. It has been reported that ethanol enhances flavone solubility 
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tion, the metabolism of both kaempferol and ethanol is mediated by cytochrome P450 
enzymes. Can the intestinal absorption of kaempferol be enhanced by ethanol? Does in-




Kaempferol was purchased from Sigma Chemical Co. (USA). HPLC-grade methanol 
and acetonitrile were purchased from Merck Co. Ltd. (Germany). All other reagents were 
of analytical grade.
Animal treatment
Twenty-four male Sprague Dawley rats weighing 250–300 g (aged 2–3 months) were 
obtained from the Experimental Animal Center of the Fourth Military Medical University 
(Xi’an, China). Animals were housed in a temperature-controlled room under 12-hour 
light-dark cycles. Animals had free access to food and water during the experimental pe-
riod. All animal experimental protocols were reviewed and approved by the Ethical Com-
mittee of Northwest A&F University for the Care and Use of Laboratory Animals (Yan-
gling, China).
Kaempferol suspension for intravenous administration was prepared by mixing in 
distilled water and a kaempferol solution for oral administration was prepared by dissolv-
ing kaempferol in ethanol.
The rats were randomly divided into six groups of four animals each: group 1 – low 
dose p.o., control group, administered 100 mg kg–1 bm kaempferol dissolved in corn oil; 
group 2 – high dose p.o. control group, administered 250 mg kg–1 bm kaempferol dissolved 
in corn oil; group 3 – low dose p.o. combination group, administered 100 mg kg–1 bm 
kaempferol dissolved in ethanol (600 mg kg–1 bm); group 4 – high dose p.o. combination 
group, administered 250 mg kg–1 bm kaempferol dissolved in ethanol (600 mg kg–1 bm); 
group 5 – low dose i.v. control group, administered 10 mg kg–1 bm kaempferol suspended 
in distilled water; group 6 – high dose i.v. control group, administered 25 mg kg–1 bm 
kaempferol suspended in distilled water.
To determine drug concentrations and to calculate the pharmacokinetic parameters, 
blood samples were drawn from the jugular vein using heparinized tubes at specified time 
intervals: 15, 30, 60, 90, 120, 240, 360, 480 and 720 min after administration. Blood samples 
were centrifuged at 3000 rpm for 10 min at 4 °C and the plasma was stored at –20 °C until 
HPLC analysis.
Sample preparation
A hundred μL of plasma with 50 μL HCl (10 mol L–1) and 100 μL acetonitrile was 
vortex-mixed for 3 min. The resulting mixture was kept in a water bath at 90 °C for 120 min 
and then 25 μL of NH4OH (7.5 mol L–1) was added. After 1.5 mL acetonitrile was added, the 
cooled sample was mixed thoroughly by vortex mixing for 2 min and centrifuged at 10,000 
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rpm for 15 min. The supernatant was discarded and the pellet with precipitated proteins 
was dried under a gentle stream of nitrogen at 38 °C (8). The residue was dissolved in 100 
μL methanol and centrifuged at 15,000 rpm for 10 min. Finally, 20 μL of the supernatant 
was injected into the HPLC system for the measurements.
Ultra-high performance liquid chromatography (UHPLC)
Filtered solutions were analyzed by UHPLC (Waters Acquity, USA) using a Waters 
BEH C18 column (1.7 μm, 50 × 2.5 mm). The mobile phase was a mixture of methanol and 
0.4 % phosphoric acid (55: 45, V/V) at a flow rate of 1.0 mL min–1. The column temperature 
was 35 °C and the UV detector wavelength was set at 360 nm (8).
Pharmacokinetic analysis
Model fitting and evaluation of the pharmacokinetic parameters were done using 
Drug and statistics 2.0 (DAS 2.0; Drug Clinical Research Center of Shanghai University of 
Traditional Chinese Medicine, Shanghai, China). Pharmacokinetic parameters were deter-
mined using the non-compartmental method based on the statistical moment theory. The 
area under the plasma concentration time curve (AUC) was calculated by the linear trap-
ezoidal method. The apparent elimination half-life (t1/2) was calculated by 0.693/k (k – the 
elimination rate constant). Total body clearance (CLz/F) was calculated by dose/AUC. Vi-
sual inspection of the data from the concentration-time curve was used to obtain the peak 
concentration (cmax) and the time to reach peak concentration (tmax) of kaempferol in plas-
ma. The apparent volume of distribution (Vz) was calculated by: dose×AUCM/AUC×AUC 
(AUCM – area under the first moment of the concentration-time curve from time zero to 
infinity). Absolute bioavailability (F, %) was estimated from the equation:
(AUCp.o. × dosei.v../ dosep.o. × AUCi.v.) × 100.
Statistical analysis
All results are presented as mean ± standard deviations (SD). Statistical analysis was 
performed using Student’s t-test. A value of p < 0.05 was taken as the level of significance.
RESULTS AND DISCUSSION
The plasma concentration time-course of kaempferol following oral administration of 
kaempferol with or without ethanol (600 mg kg–1 bm) is illustrated in Fig. 1 and the follow-
ing intravenous administration in Fig. 2. Pharmacokinetic parameters of kaempferol are 
listed in Table I.
Compared to the oral control groups (100 and 250 mg kg–1 bm of kaempferol), the 
significantly decreased area under the plasma concentration-time curve and the concen-
tration peak of oral kaempferol showed that co-administration of ethanol improved 
kaempferol absorption (100 mg kg–1 bm, p < 0.05; 250 mg kg–1 bm, p < 0.01). Decreased total 
body clearance (CLz/F) in the case of ethanol co-administration (100 mg kg–1 bm, p < 0.05 
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and 250 mg kg–1 bm, p < 0.05) indicated reduced clearance of kaempferol. Since drug bio-
availability (F) depends on the extent of absorption and the rate of total body clearance, in 
oral control groups it was 3.1 % (100 mg kg–1 bm) and 2.1 % (250 mg kg–1 bm) for kaemp-
ferol but it was significantly increased by 4.3 %, namely, 2.8 % (p < 0.05 and p < 0.01, resp.) 
during ethanol co-administration. Meanwhile, the apparent volume of distribution (Vz) 
and the time to reach cmax (tmax) of kaempferol after oral co-administration of ethanol 
changed, but not significantly.
Fig. 1. Mean plasma concentration after oral administration of kaempferol (K) (100 and 250 mg kg–1 
bm, n = 4) with or without ethanol (E), in rats. Bars represent the standard deviation.
Fig. 2. Mean plasma concentration after intravenous (10 and 25 mg kg–1 bm, n = 4) administration of 
kaempferol (K), in rats. Bars represent the standard deviation.
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Flavonoid absorption is affected by the permeability of the membrane (9). It is known 
that ethanol could enhance the cell membrane permeability by breaking cell-membrane 
integrity and stability (10), co-administration of ethanol could therefore accelerate the ab-
sorption of kaempferol. Three cytochrome P450s enzymes, CYP2E1, CYP1A2 and CYP3A4, 
play a major role in ethanol metabolism in the liver (11, 12), and CYP1A2 is also involved 
in the metabolism of kaempferol, as confirmed in a previous in vitro study (13). As a potent 
inhibitor of CYP2E1 and CYP 3A4, kaempferol can inhibit ethanol metabolism (14, 15). In 
our investigations, kaempferol and ethanol co-administration clearly increased the AUC 
(Fig. 1) and bioavailability (Table I) of kaempferol, suggesting that competition of ethanol 
and kaempferol on CYP1A2 may inhibit kaempferol metabolism.
CONCLUSIONS
The fact that ethanol co-administration enhances bioavailability of kaempferol dem-
onstrated the vital role of kaempferol in protection against alcoholic liver diseases. This 
study may be helpful for medical exploration in alcoholic liver disease interventions.
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10 25 100 250 100 250 
AUC 
(mg L–1 h–1) 2.89 ± 0.18 7.17 ± 0.41 0.89 ± 0.02 1.51 ± 0.07 1.24 ± 0.12* 1.93 ± 0.06
##
t1/2 (h) 3.51 ± 0.19 3.45 ± 0.12 5.34 ± 0.66 3.47 ± 0.70 3.59 ± 0.82* 2.70 ± 0.09#
tmax (h) 0.25 0.25 1.50 1.00 1.50 1.00
CLz/F 
(L kg h–1) 3.33 ± 0.22 3.36 ± 0.20 70.71 ± 4.344 130.99 ± 14.356 60.59 ± 6.54* 110.90 ± 5.321
#
Vz (L kg–1) 16.82 ± 0.54 16.70 ± 0.59
1665.51 ± 
110.80 1573.01 ± 150.32 1458.78 ± 173.82 1360.21 ± 56.73
cmax 
(mg L–1) 1.54 ± 0.14 3.84 ± 0.34 0.18 ± 0.01 0.46 ± 0.03 0.26 ± 0.01* 0.59 ± 0.02
#
F (%) – – 3.07 ± 0.05 2.11 ± 0.10 4.30 ± 0.42* 2.69 ± 0.21##
Significant difference compared to: 100 mg kg–1 bm kaempferol group;* p < 0.05, **p < 0.01; 250 mg k–1 bm kaempferol 
group: # p < 0.05, ## p < 0.01.
Ethanol dose is 600 mg kg–1 bm.
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